20:05 EST Cathie Wood’s ARK Investment bought 409.5K shares of Crispr Therapeutics (CRSP) today
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- Crispr Therapeutics price target lowered to $53 from $59 at Stifel
- Crispr Therapeutics price target lowered to $55 from $59 at Barclays
- CRISPR Therapeutics Advances with Solid Financials and Approvals
- Crispr Therapeutics reports Q3 EPS ($1.01), consensus ($1.42)
- Crispr Therapeutics options imply 8.9% move in share price post-earnings